Data showed there was brisk buying by qualified institutional investors (QIBs), whose quota limit was subscribed 79 per cent.

The offer received bids for 76,780 shares as against 52,50,001 shares on offer, which are available in the price band of Rs 680-730 apiece.

The issue is an offer for sale (OFS) wherein existing promoter entity is looking to offload its 27.75 per cent holding in the mattress comp...

The issue is an offer for sale (OFS), wherein existing promoter entity Polyflex Marketing is looking to offload its 27.75 per cent holding ...

Considering the issue as undersubscribed, the merchant banker along with the company will start the process of unblocking funds.

Nifty50 futures on the Singapore Stock Exchange were trading 66 points higher at 8,056, indicating a higher opening for the domestic market.

First it was the poor debut for Varun Beverages (VBL) and then came the IPO of GreenSignal Bio, which did not get the required bids during ...

It was a Black Friday for the domestic equity market, which saw the BSE benchmark Sensex clock its second-biggest percentage fall of 2016.

Data showed non-institutional investors subscribed to just 12 per cent of the quota limit of 21,86,934 shares while retail individual inves...

Data showed non-institutional investors subscribed to just 10 per cent of the quota limit of 21,86,934 shares while RIIs bade for 5.98 time...

The portion set aside for non institutional investors was subscribed 2 per cent, while that of retail investors got oversubscribed 1.59 tim...

GSBPL is one of the four companies worldwide who have been WHO-prequalified to supply the BCG vaccine to UNICEF.

Gland Pharma makes and markets specialised injectable formulations for generic versions of drugs, it also manufactures a limited quantity o...

Competition Commission of India (CCI) has given nod for the proposal, which involves multiple transactions, saying the deal does not raise ...

India had revenue of $ 665 million in this space which was expected to reach $ 800 million soon, said Steven H Myint.

From being a low-margin pharma manufacturer, Aurobindo Pharma is transforming itself into a high-margin formulations player.

ET takes a ringside view of the status of SEZs - expected to attract over Rs 40,000 crore in five years.